Compass Pathways Plc (CMPS)

Currency in USD
10.96
+1.59(+16.97%)
Closed·
11.00+0.05(+0.46%)
·
Trading near 52-week High
CMPS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.6111.08
52 wk Range
2.2511.08
Key Statistics
Prev. Close
10.96
Open
9.85
Day's Range
9.61-11.08
52 wk Range
2.25-11.08
Volume
8.64M
Average Volume (3m)
4.6M
1-Year Change
178.2051%
Book Value / Share
-0.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CMPS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
21.43
Upside
+95.52%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Compass Pathways Plc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

13 Buy
1 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 21.43
(+95.52% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy29.00+164.60%-Maintain13/05/2026
BTIG
Buy14.00+27.74%-Maintain13/05/2026
RBC Capital
Buy22.00+100.73%21.00Maintain13/05/2026
Jefferies
Buy18.00+64.23%-New Coverage04/05/2026
H.C. Wainwright
Buy70.00+538.69%-Maintain28/04/2026

Compass Pathways Plc SWOT Analysis


Psychedelic Pionee
Compass Pathways leads the charge in developing psilocybin-based therapy COMP360 for treatment-resistant depression, navigating clinical trials and regulatory hurdles
Market Potential
Analysts project peak revenues of $2.3 billion for COMP360, with a potential market exceeding $1 billion in treatment-resistant depression alone
Regulatory Landscape
Explore how Compass Pathways' methodical approach aligns with FDA guidance, potentially expediting approval in an evolving regulatory environment for psychedelic therapies
Financial Outlook
With analyst price targets ranging from $12 to $60, Compass Pathways faces challenges but maintains a strong liquidity position as it advances towards commercialization
Read full SWOT analysis

Compass Pathways Plc Earnings Call Summary for Q4/2024

  • Q4 2024 EPS met forecast at -0.63; stock rose 7.03% premarket to $3.96 despite no revenue
  • Net loss of $155.1M for 2024; R&D expenses increased to $119M from $87.5M in 2023
  • Cash runway extended to H2 2026 with $165.1M cash on hand and $140M from January financing
  • Over 90% recruitment for COMP005 Phase III trial; top-line data expected Q2 2025
  • 2025 guidance: $120M-$145M net cash used in operations; focus on TRD and PTSD opportunities
Last Updated: 27/02/2025, 14:08
Read Full Transcript

Earnings

Latest Release
13/05/2026
EPS / Forecast
-0.30 / -0.43
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare CMPS to Peers and Sector

Metrics to compare
CMPS
Peers
Sector
Relationship
P/E Ratio
−5.1x−2.5x−0.5x
PEG Ratio
0.130.010.00
Price/Book
−28.0x7.0x2.6x
Price / LTM Sales
-6.0x3.2x
Upside (Analyst Target)
85.4%155.5%50.6%
Fair Value Upside
Unlock6.3%7.1%Unlock

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
8.22M6.09%76.98M
Other Institutional Investors
67.96M50.37%636.75M
Public Companies & Retail Investors
58.75M43.54%550.50M
Total
134.92M100.00%1.26B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Deep Track Biotechnology Master Fund, Ltd6.87%9,274,58986,903
RTW Investments, LP6.49%8,757,39082,057

People Also Watch

121.935
AXTI
-0.79%
39.37
FLY
+0.13%
5.020
KOPN
-6.17%
4.240
ATAI
+2.17%
41.460
MRAM
-5.79%

FAQ

What Is the Compass Pathways (NASDAQ: CMPS) Share Price Today?

The Compass Pathways stock price today is 10.96 USD.

What Stock Exchange Does Compass Pathways (CMPS) Trade On?

Compass Pathways is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Compass Pathways?

The stock symbol (also called a 'ticker') for Compass Pathways is "CMPS."

What Is the Current Compass Pathways Market Capitalisation?

As of today, Compass Pathways (NASDAQ: CMPS) market cap is 1.48B USD.

What Is Compass Pathways's (CMPS) Earnings Per Share (TTM)?

The Compass Pathways EPS is currently -3.08 (Trailing Twelve Months).

When Is the Next Compass Pathways Earnings Date?

Compass Pathways's next earnings report will be released on 30/07/2026.

Is CMPS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Compass Pathways moving averages and other technical indicators, the daily buy/sell signal for CMPS stock is Strong Buy.

How Many Times Has Compass Pathways Stock Split?

Compass Pathways has split 0 times. (See the CMPS stock split history page for full effective split date and price information.)

How Many Employees Does Compass Pathways Have?

Compass Pathways has 156 employees, based on their latest Companies House report.

What is the current trading status of Compass Pathways (NASDAQ: CMPS)?

As of 14/05/2026, Compass Pathways (CMPS) is trading at a share price of 10.96 USD, with a previous close of 10.96 USD. The stock has fluctuated within a day range of 9.61 USD to 11.08 USD, while its 52-week range spans from 2.25 USD to 11.08 USD.

What Is Compass Pathways (CMPS) Price Target According to Analysts?

The average 12-month price target for Compass Pathways is 21.43 USD, with a high estimate of 70 USD and a low estimate of 8 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +95.52% Upside potential.

What Is the CMPS After Hours Price?

CMPS's last after hours stock price is 11.00 USD, the stock has decreased by 0.05, or 0.46%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.